Ivonescimab First-Line Biliary Tract Cancer Phase III Overall Survival Data Selected as ESMO Late-Breaking Abstract; Nearly 30 Akeso Studies to Be Presented at ESMO 2026

ConferenceIvonescimabPositive

AI Analysis

Summary

Akeso announced that ivonescimab Phase III overall survival data in first-line biliary tract cancer has been selected as a late-breaking abstract for ESMO 2026. The company will present nearly 30 clinical studies at the congress.

Clinical Trial Data

Phase

Phase 3

Outcome Details

Ivonescimab first-line biliary tract cancer Phase III overall survival data selected as ESMO late-breaking abstract

Importance:6/10

Sentiment:

0.60

ESMO Congressbispecific antibodieslate-breaking abstractfirst-in-classoncology

Related Companies

$DFPH $MDCE $TRAX

Read the original article

Published by PR Newswire Pharma on September 21, 2026 11:46 PM

Read Original